Featured

Status

Health Topics

Any Category
Clear Filters

Search Clinical Trials

133 Results
Completed
Effects of Ethanol on the Pharmacokinetics of PT-150 (Formerly ORG34517) (PT150 PK Study)
This study can be classified as a phase 1, single center, and drug-drug interaction (DDI) study. The within-subjects' experimental procedures will assess pharmacokinetic interactions between ethanol (EtOH) and PT150 (900 …
Baylor Role: Collaborator
Recruiting
Integrated Tele-Behavioral Activation and Fall Prevention for Low-income Homebound Seniors With Depression
Depression and falls are significantly higher in low-income, racially diverse homebound seniors than in the general older-adult population; however, the existing systems of care are not equipped to address disparities …
Baylor Role: Collaborator
Recruiting
XEN1101 for Major Depressive Disorder
This project is designed to examine the neuronal KCNQ2/3 potassium (K+) channel subtype as a novel treatment target for mood disorders through the administration of the KCNQ-selective channel opener XEN1101 …
Baylor Role: Collaborator
Completed
Parent-based Treatment for Youth With Anxiety and Obsessive-compulsive Disorder
Anxiety and obsessive-compulsive disorders are the most common mental health disorders in childhood and adolescence. Parental accommodation of their children's avoidance, escape, safety behaviors are a set of parenting behaviors …
Baylor Role: Lead Sponsor
Active, Not Recruiting
Phase II Adaptive Deep Brain Stimulation for Obsessive-Compulsive Disorder
ENROLLMENT: A subject is considered enrolled upon signing informed consent and deemed eligible to be screened by the investigator. The informed consent process may include discussions with the patients family …
Baylor Role: Lead Sponsor
Active, Not Recruiting
Brain Recordings in Patients Undergoing Deep Brain Stimulation (DBS) for Severe Obsessive-Compulsive Disorder (OCD)
Obsessive-compulsive disorder effects approximately 2-3% of the population. The only established first-line treatments for OCD are cognitive-behavioral therapy (CBT) with exposure/response prevention and serotonin reuptake inhibitor medications (SRIs). Approximately 30-40% …
Baylor Role: Lead Sponsor
Completed
Targeting HIV Retention and Improved Viral Load Through Engagement ('THRIVE')
Poor retention in HIV primary care results in lower rates of HIV viral suppression, higher rates of HIV transmission, and exacerbates racial and ethnic disparities in health outcomes, including survival. …
Baylor Role: Lead Sponsor
Recruiting
Hypoactive Sexual Desire Disorder in Males
This pilot randomized placebo controlled study will include 60 men (30 treatment and 30 placebo). ARM 1 will take flibanserin 100mg orally every night and ARM 2 will take a …
Withdrawn
Individual Versus Group Exposure With Response Prevention (ERP) for the Treatment of Obsessive Compulsive Disorder (OCD)
The purpose of the following study is to observe the effectiveness of group Exposure and Response Prevention verses individual Exposure and Response Prevention on patients with OCD for the use …
Baylor Role: Lead Sponsor
Completed
Pimavanserin for Insomnia In Veterans With Posttraumatic Stress Disorder
More treatments are needed to target insomnia in Veterans with Posttraumatic Stress Disorder. There is evidence to suggest that pimavanserin, a medication approved by the Food and Drug Administration for …
Baylor Role: Lead Sponsor